Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866592 · ClinicalTrials.gov registry record · Phase 4
Vascular Inflammation in Psoriasis - Extension Study
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT01866592: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT01866592 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01866592, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.
Interventions
- DRUG Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-10-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866592
The ClinicalTrials.gov registry entry for NCT01866592 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adalimumab is the first listed.
NCT01866592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01866592 about?
NCT01866592 is a clinical study titled "Vascular Inflammation in Psoriasis - Extension Study". VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedure...
What is the current status of trial NCT01866592?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2013-04. Estimated completion is 2016-10-27.
What interventions are being tested in trial NCT01866592?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT01866592?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.